Drugplain

temazepam 30 mg/1

temazepam · CAPSULE · Bryant Ranch Prepack

2 Recalls on Record
Plain English

temazepam is a capsule containing temazepam at 30 mg/1, taken oral. Manufactured by Bryant Ranch Prepack.

Key Facts

Brand Name
temazepam
Generic Name
temazepam
NDC Code (Product)
72162-1825
Manufacturer
Bryant Ranch Prepack
Strength
30 mg/1
Dosage Form
CAPSULE
Route
ORAL
Marketing Status
DEA Schedule
Schedule IV (Controlled)
Application #
ANDA071457
Drug Class
Benzodiazepine [EPC]
Marketing Start
04/21/1987

Recall History

2 Recalls on Record
Class III12/22/2016

Vintage Pharmaceuticals LLC, DBA Qualitest Pharmaceuticals

Failed Stability Specifications

TerminatedVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling: Label Mixup: TEMAZEPAM, Capsule, 7.5 mg may have potentially been mislabeled as one of the following drugs: CALCIUM CITRATE, Tablet, 200 mg Elemental Calcium, NDC 00904506260, Pedigree: AD28333_1, EXP: 5/8/2014; VALSARTAN, Tablet, 160 mg, NDC 00078035934, Pedigree: AD49414_7, EXP: 5/17/2014.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

fatigue2,158 reports
toxicity to various agents2,125 reports
drug ineffective1,938 reports
nausea1,758 reports
pain1,729 reports
headache1,708 reports
death1,456 reports
off label use1,419 reports
diarrhoea1,372 reports
dyspnoea1,354 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.

Dosage & Administration

DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly ( see WARNINGS , Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE : Dependence ).

Warnings

WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including temazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe temazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of temazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking temazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when temazepam is used

Adverse Reactions

ADVERSE REACTIONS During controlled clinical studies in which 1076 patients received temazepam at bedtime, the drug was well tolerated. Side effects were usually mild and transient. Adverse reactions occurring in 1% or more of patients are presented in the following table: Temazepam % Incidence (n=1076) Placebo % Incidence (n=783) Drowsiness 9.1 5.6 Headache 8.5 9.1 Fatigue 4.8 4.7 Nervousness 4.6 8.2 Lethargy 4.5 3.4 Dizziness 4.5 3.3 Nausea 3.1 3.8 Hangover 2.5 1.1 Anxiety 2.0 1.5 Depression 1.7 1.8 Dry Mouth 1.7 2.2 Diarrhea 1.7 1.1 Abdominal Discomfort 1.5 1.9 Euphoria 1.5 0.4 Weakness 1.4 0.9 Confusion 1.3 0.5 Blurred Vision 1.3 1.3 Nightmares 1.2 1.7 Vertigo 1.2 0.8 The following adverse events have been reported less frequently (0.5% to 0.9%): Central Nervous System – anorexia, ataxia, equilibrium loss, tremor, increased dreaming Cardiovascular – dyspnea, palpitations Gastrointestinal – vomiting Musculoskeletal – backache Special Senses – hyperhidrosis, burning eyes Amnesia, hallucinations, horizontal nystagmus, and paradoxical reactions including restlessness, overstimulation and agitation were rare (less than 0.5%). To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pha

Frequently Asked Questions

What is temazepam used for?

temazepam contains temazepam. It is a capsule taken oral. Consult your doctor for specific uses.

Is temazepam a controlled substance?

Yes, temazepam is classified as CIV under the DEA Controlled Substances Act.

What is the generic name for temazepam?

The generic name for temazepam is temazepam. There are 4 other brand versions of temazepam.

What is the NDC code for temazepam 30 mg/1?

The NDC (National Drug Code) for temazepam 30 mg/1 is 72162-1825, listed by Bryant Ranch Prepack.

Product NDC

72162-1825

Package NDC

72162-1825-1

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)